艾托珠单抗在溃疡性结肠炎中的临床潜力：炒作与希望。
The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes.
作者信息
Fiorino Gionata, Gilardi Daniela, Danese Silvio
机构信息
IBD Center, Department of Gastroenterology, Humanitas Research Hospital, Rozzano, Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Via Manzoni 113, 20089 Rozzano, Milan, Italy.
出版信息
Therap Adv Gastroenterol. 2016 Jul;9(4):503-12. doi: 10.1177/1756283X16647935. Epub 2016 May 19.
Abstract
Antiadhesion molecules are effective and safe in patients with ulcerative colitis (UC). Etrolizumab, a monoclonal antibody targeting both α4β7 and αEβ7, represents a promising therapy for patients with UC, since this novel mechanism of action may be effective in blocking leukocyte recruitment both at the vascular and at the mucosal level. Preliminary studies show that etrolizumab is effective in inducing clinical response and remission, and mucosal healing. Moreover, new predictors of response have recently been identified, opening the way to a tailored therapeutic approach. This review of the literature aims to present and discuss the most recent evidence on etrolizumab in UC, focusing on the clinical implications of the use of etrolizumab in UC.
摘要
抗粘附分子对溃疡性结肠炎（UC）患者有效且安全。etrolizumab是一种靶向α4β7和αEβ7的单克隆抗体，对UC患者来说是一种有前景的治疗方法，因为这种新的作用机制可能在血管和黏膜水平有效阻断白细胞募集。初步研究表明，etrolizumab在诱导临床反应、缓解及黏膜愈合方面有效。此外，最近已确定了新的反应预测指标，为个性化治疗方法开辟了道路。这篇文献综述旨在介绍和讨论关于etrolizumab治疗UC的最新证据，重点关注etrolizumab在UC治疗中的临床意义。
相似文献
1
The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes.艾托珠单抗在溃疡性结肠炎中的临床潜力：炒作与希望。
Therap Adv Gastroenterol. 2016 Jul;9(4):503-12. doi: 10.1177/1756283X16647935. Epub 2016 May 19.
2
Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease.综述文章：依特利珠单抗（一种用于炎症性肠病的抗β7 整合素治疗药物）的非临床和临床药理学、药代动力学和药效学。
Aliment Pharmacol Ther. 2018 Jun;47(11):1440-1452. doi: 10.1111/apt.14631. Epub 2018 Mar 30.
3
Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins?维得利珠单抗和埃妥珠单抗治疗溃疡性结肠炎：双胞胎还是表亲？
Expert Opin Biol Ther. 2020 Apr;20(4):353-361. doi: 10.1080/14712598.2020.1717465. Epub 2020 Jan 21.
4
Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis.溃疡性结肠炎患者结肠活检中整合素 αE 和颗粒酶 A 的表达与依特罗珠单抗应答的关系。
Gastroenterology. 2016 Feb;150(2):477-87.e9. doi: 10.1053/j.gastro.2015.10.041. Epub 2015 Oct 30.
5
Etrolizumab for ulcerative colitis: the new kid on the block?艾托珠单抗用于溃疡性结肠炎：初来乍到者？
Expert Opin Biol Ther. 2016;16(4):567-72. doi: 10.1517/14712598.2016.1158807.
6
Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial.依特立珠单抗诱导治疗溃疡性结肠炎的随机对照 2 期临床试验
Lancet. 2014 Jul 26;384(9940):309-18. doi: 10.1016/S0140-6736(14)60661-9. Epub 2014 May 9.
7
Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating β7 Receptor Occupancy in Patients With Ulcerative Colitis.溃疡性结肠炎患者血清依特立珠单抗的药代动力学和药效学建模及循环β7 受体占有率。
J Clin Pharmacol. 2018 Mar;58(3):386-398. doi: 10.1002/jcph.1031. Epub 2017 Nov 26.
8
Etrolizumab versus infliximab in the treatment of induction phase of ulcerative colitis: A systematic review and indirect comparison.依特利珠单抗与英夫利昔单抗治疗溃疡性结肠炎诱导缓解期的疗效比较：系统评价和间接比较。
Pharmacol Res. 2019 Jan;139:120-125. doi: 10.1016/j.phrs.2018.11.003. Epub 2018 Nov 3.
9
Assessment of Disease-Related Therapeutic Protein Drug-Drug Interaction for Etrolizumab in Patients With Moderately to Severely Active Ulcerative Colitis.评估依曲珠单抗在中度至重度活动性溃疡性结肠炎患者中与疾病相关的治疗性蛋白质药物相互作用
J Clin Pharmacol. 2016 Jun;56(6):693-704. doi: 10.1002/jcph.649. Epub 2016 Jan 11.
10
Etrolizumab-s Does Not Induce Residual Trafficking of Regulatory T Cells.依特立珠单抗不会诱导调节性 T 细胞的残留转运。
Inflamm Bowel Dis. 2022 Nov 2;28(11):1746-1755. doi: 10.1093/ibd/izac137.
引用本文的文献
1
Efficacy and safety of etrolizumab in the treatment of inflammatory bowel disease: a meta-analysis.依特利珠单抗治疗炎症性肠病的疗效和安全性：一项荟萃分析。
PeerJ. 2024 Aug 23;12:e17945. doi: 10.7717/peerj.17945. eCollection 2024.
2
Meta-analysis of etrolizumab placebo in ulcerative colitis: safety and efficacy outcomes.在溃疡性结肠炎中进行的依法珠单抗与安慰剂对比的荟萃分析：安全性和疗效结果
Therap Adv Gastroenterol. 2024 Jun 7;17:17562848241253685. doi: 10.1177/17562848241253685. eCollection 2024.
3
Treatment of Inflammatory Bowel Disease: A Comprehensive Review.炎症性肠病的治疗：全面综述
Front Med (Lausanne). 2021 Dec 20;8:765474. doi: 10.3389/fmed.2021.765474. eCollection 2021.
4
Anti-Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives.用于治疗炎症性肠病的抗整合素：当前证据与展望
Clin Exp Gastroenterol. 2021 Aug 24;14:333-342. doi: 10.2147/CEG.S293272. eCollection 2021.
5
Probiotics for induction of remission in ulcerative colitis.用于诱导溃疡性结肠炎缓解的益生菌。
Cochrane Database Syst Rev. 2020 Mar 4;3(3):CD005573. doi: 10.1002/14651858.CD005573.pub3.
6
Probiotics for maintenance of remission in ulcerative colitis.用于维持溃疡性结肠炎缓解的益生菌。
Cochrane Database Syst Rev. 2020 Mar 4;3(3):CD007443. doi: 10.1002/14651858.CD007443.pub3.
7
Emerging treatments for inflammatory bowel disease.炎症性肠病的新兴治疗方法。
Ther Adv Chronic Dis. 2020 Feb 5;11:2040622319899297. doi: 10.1177/2040622319899297. eCollection 2020.
8
Improving IBD Care: A Personalized Approach to Management.改善炎症性肠病护理：个性化管理方法
Gastroenterol Hepatol (N Y). 2018 Mar;14(3):1-20.
9
αEβ7, α4β7 and α4β1 integrin contributions to T cell distribution in blood, cervix and rectal tissues: Potential implications for HIV transmission.αEβ7、α4β7和α4β1整合素对T细胞在血液、宫颈和直肠组织中分布的作用：对HIV传播的潜在影响
PLoS One. 2018 Feb 8;13(2):e0192482. doi: 10.1371/journal.pone.0192482. eCollection 2018.
本文引用的文献
1
Integrins and adhesion molecules as targets to treat inflammatory bowel disease.整合素和黏附分子作为治疗炎症性肠病的靶点。
Curr Opin Pharmacol. 2015 Dec;25:67-71. doi: 10.1016/j.coph.2015.11.007.
2
Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis.溃疡性结肠炎患者结肠活检中整合素 αE 和颗粒酶 A 的表达与依特罗珠单抗应答的关系。
Gastroenterology. 2016 Feb;150(2):477-87.e9. doi: 10.1053/j.gastro.2015.10.041. Epub 2015 Oct 30.
3
Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group.那他珠单抗相关进行性多灶性白质脑病风险的分层与监测：专家组建议
J Neurol Neurosurg Psychiatry. 2016 Feb;87(2):117-25. doi: 10.1136/jnnp-2015-311100. Epub 2015 Oct 22.
4
Complications of biologics in inflammatory bowel disease.生物制剂在炎症性肠病中的并发症。
Curr Opin Gastroenterol. 2015 Jul;31(4):296-302. doi: 10.1097/MOG.0000000000000191.
5
Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases.靶向白细胞与内皮细胞相互作用的药物开发和炎症性肠病的治疗方案。
Gastroenterology. 2014 Nov;147(5):981-9. doi: 10.1053/j.gastro.2014.08.044. Epub 2014 Sep 16.
6
Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis.中度至重度溃疡性结肠炎的生物制剂：系统评价和网络荟萃分析。
Ann Intern Med. 2014 May 20;160(10):704-11. doi: 10.7326/M13-2403.
7
Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial.依特立珠单抗诱导治疗溃疡性结肠炎的随机对照 2 期临床试验
Lancet. 2014 Jul 26;384(9940):309-18. doi: 10.1016/S0140-6736(14)60661-9. Epub 2014 May 9.
8
Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.英夫利昔单抗联合硫唑嘌呤治疗溃疡性结肠炎优于两药单药治疗。
Gastroenterology. 2014 Feb;146(2):392-400.e3. doi: 10.1053/j.gastro.2013.10.052.
9
Etrolizumab: anti-β7-a novel therapy for ulcerative colitis.依特珠单抗：抗β7——溃疡性结肠炎的一种新型疗法。
Gastroenterology. 2014 Jan;146(1):307-9. doi: 10.1053/j.gastro.2013.11.013. Epub 2013 Nov 21.
10
Vedolizumab as induction and maintenance therapy for Crohn's disease.维得利珠单抗作为克罗恩病的诱导缓解和维持治疗药物。
N Engl J Med. 2013 Aug 22;369(8):711-21. doi: 10.1056/NEJMoa1215739.
Zotero 插件